Maynard Um
-
-
-
-
-
-
-
Baird on Dyne Therapeutics (DYN): 'Positive on clinical progress and improved regulatory dynamic'
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $50 at H.C. Wainwright
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Raised to $21 at Bernstein SocGen Group, we see risk-reward as favorable
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Dyne Therapeutics Inc. (DYN) Announces Proposed $200M Share Offering
-
-
-
-
-
-
-
Oppenheimer Assumes Dyne Therapeutics (DYN) at Outperform (correction)
-
396,984 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

